Study of firm-level strategic alliances drivers; case study Pharmaceutical industry
Commercialization is one of the essential element for development in The biotechnology industry. Nowadays Successful Commercialization is critical for surviving in the competitive markets. Commercialization is delivering of technical inventions to the market for profits, and includes the processes...
| Format: | Article |
|---|---|
| Language: | fas |
| Published: |
University of Sistan and Baluchestan
2015-05-01
|
| Series: | پژوهشهای مدیریت عمومی |
| Subjects: | |
| Online Access: | https://jmr.usb.ac.ir/article_2062_2934edbc00f272c207e38cbcedc56df3.pdf |
| Summary: | Commercialization is one of the essential element for development in The biotechnology industry. Nowadays Successful Commercialization is critical for surviving in the competitive markets. Commercialization is delivering of technical inventions to the market for profits, and includes the processes and activities that bridge the gap between the economic value and the realization that the true economic value. establishing strategic alliances between pharmaceutical companies and biopharmaceutical companies in biomedical industry has become the dominant mode of innovation commercialization. Establishing strategic alliances between firms is one of the important issues that have been addressed in this paper. The survey of 30 experts on the pharmaceutical industry, seven hypotheses using t- student test results - and 8 hypothesis testing by factor analysis within cases led to the eight hypothesis supported and five of the seven hypotheses confirmed the drivers of strategic alliance capability in priority order are: access to complementary assets, the dynamic capability of alliance management, organizational learning, social capital, and mechanisms that reduce the choice uncertainty of coalition partners. |
|---|---|
| ISSN: | 2538-3418 2676-7880 |